Several therapies specifically target EGFR and its signaling pathways. The most well-known are tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib, and osimertinib, which are used primarily in the treatment of EGFR-mutant non-small cell lung cancer. Monoclonal antibodies like cetuximab and panitumumab, which target the extracellular domain of EGFR, are used in the treatment of colorectal cancer and head and neck cancers. Additionally, combination therapies involving EGFR inhibitors and other treatment modalities, such as chemotherapy and radiation, are being explored.
